IBS Monitoring with Pill Tracker – Easy Management
revolutionary Biosensor Pill Promises Non-Invasive Detection of intestinal Inflammation
Table of Contents
A groundbreaking ingestible biosensor pill, developed by researchers at Brigham and Women’s hospital (BWH), offers a simple, affordable, and non-invasive method for detecting intestinal inflammation, potentially transforming the management of inflammatory bowel disease (IBD).
Boston, MA – A novel “biosensor pill” that can be swallowed like a regular medication could revolutionize how patients and doctors monitor intestinal inflammation.Developed by investigators in the Innovative Biomaterials Lab at Brigham and Women’s Hospital (BWH), a founding member of the Mass General Brigham health care system, this ingestible device offers a user-friendly and cost-effective choice to current diagnostic methods.
“This paper introduces a simple and affordable solution: an ingestible ‘biosensor pill’ that could be swallowed, like any other pill,” explained one of the lead investigators.”With further advancement and testing in humans, this swallowable sensor could help patients and doctors catch flare-ups earlier, adjust treatments more effectively, and ultimately improve quality of life without the hassle of stool handling or hospital visits.”
The PRIM Pill: A Simple Yet Powerful Diagnostic Tool
The innovative device, dubbed the PRIM (Pill for Responsive Ingestible Monitoring) pill, is a small capsule coated with a specialized polymer. This polymer is designed to react specifically to the presence of inflammation within the gut.
How the PRIM Pill Works
when inflammation is present, it leads to an increase in reactive oxygen species (ROS), which are chemical markers of inflammation. the PRIM pill’s unique polymer coating breaks down in the presence of elevated ROS levels. This breakdown triggers the release of a visible blue dye. The presence of this blue dye in a patient’s stool serves as a clear, visual signal indicating intestinal inflammation.
Rigorous Testing and Promising Results
The research team conducted extensive testing of the PRIM pill in both laboratory settings and a rat model of colitis, a condition characterized by inflammation of the colon. Across 36 capsules used in the study, the device demonstrated remarkable efficacy in distinguishing between healthy and inflamed conditions.
In rats diagnosed with colitis, the miniaturized PRIM device successfully identified intestinal inflammation with a sensitivity of 78% and a specificity of 72%. Crucially, the blue dye released by the pill was clearly visible in the stool of the inflamed rats. In contrast, the device remained intact and inactive in healthy rats, confirming its stability and specificity under non-inflammatory conditions.
Future Directions and Accessibility
The research team is now focused on adapting the PRIM pill for human use. This next phase of development involves testing the device in larger animal models and refining its sensitivity to accurately detect even mild to moderate levels of inflammation.
A significant advantage of the PRIM pill is its projected affordability. The estimated production cost for each unit is a mere $0.38,making it a highly accessible diagnostic tool for widespread use.
“This innovative device could transform how physicians monitor IBD by giving patients a clear, visual signal they can check at home,” said co-senior author Caitlin L. Maikawa, PhD, a former postdoctoral researcher in Lee’s lab at BWH, who is now an assistant professor at the University of Toronto’s Institute of Biomedical Engineering. “It’s designed to be low-cost,easy to use,and accessible for patients at home.”
This development holds immense promise for improving the lives of individuals suffering from IBD and other inflammatory gut conditions, offering a more convenient and patient-centric approach to disease management.
Reference: Zhuang Z, Huang LL, Seo BC, et al. A radically simple, ingestible colorimetric biosensor pill for cost-effective, non-invasive monitoring of intestinal inflammation. Device. doi: 10.1016/j.device.2025.100865
This article has been republished from materials provided by Brigham and Women’s Hospital. Note: material may have been edited for length and content. For further data, please contact the cited source.*